Trial record 1 of 1 for:    EA6134
Previous Study | Return to List | Next Study

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02224781
Recruitment Status : Recruiting
First Posted : August 25, 2014
Last Update Posted : March 13, 2018
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : October 2, 2022
  Study Completion Date : No date given